Interview With David Champion
Maya Health’s Co-Founder and CEO, David Champion, discusses the importance of data and analytics in the growing psychedelic community.
Maya Health’s Co-Founder and CEO, David Champion, discusses the importance of data and analytics in the growing psychedelic community.
Algernon Pharmaceuticals has received FDA approval to study DMT for use in stroke patients to help rebuild synaptic connections.
What is psilohuasca? This psychedelic combo marries MAO inhibitors with psilocin for an extended journey into healing.
Research into ketamine as a potential treatment for Parkinson’s patients suffering from drug side effects is getting FDA approval.
Could psychedelics help people suffering from color blindness? New research sees great potential with lsd and psilocybin.
Here’s MindMed’s (MMED / MNMD / MMQ) Q1 2021 recorded Earnings call! Soon we will upload a video detailing all the highlights but for now, for those who are interested in listening to the entire call, you can listen to it here!
Enjoy!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MindMedNews #MNMD
Researchers personally trying MDMA, a new company on the block, financial results for MindMed (MMED / MNMD / MMQ) & Compass Pathways (CMPS) & news on Numinus Wellness (NUMI) & Red Lights Holland (TRIP/TRUFF), this is what we will be covering in today’s episode.
Timestamps:
0:00 – Intro
0:18 – FDA clears researchers to test MDMA on themselves
1:55 – MindMed (MMED / MNMD) announces Q1 Financials
4:30 – Compass Pathways (CMPS) announces Q1 Financials
6:56 – Numinus Wellness (NUMI) supplies psilocybin extract to Optimi Health
8:17 – Red Light Holland (TRIP / TRUFF) has a new app called ‘iMicro’
9:31 – Wesana Health Holdings (WESA) begins trading on the CSE
Link to the FDA clearing researchers to test MDMA on themselves:
https://www.marijuanamoment.net/fda-clears-researchers-to-study-mdma-use-by-therapists-being-trained-in-psychedelic-medicine/
Link to Mindmed’s Q1 2021 Financial report and business highlights:
https://www.newswire.ca/news-releases/mindmed-announces-2021-q1-financial-results-cash-balance-of-160m-usd-194m-cad-to-execute-on-diverse-clinical-pipeline-816112809.html
Link to Compass Pathways (CMPS) Q1 Financial report:https://www.globenewswire.com/news-release/2021/05/13/2228969/0/en/COMPASS-Pathways-plc-announces-financial-results-and-business-highlights-for-the-first-quarter-2021.html
Link to Numinus (NUMI) supplying psilocybin extract to Optimi Health:
https://psilocybinalpha.com/news/numinus-wellness-and-optimi-health-submit-all-natural-psilocybin-extract-to-health-canada-for-pre-clinical-trial-application
Link to Red Light Holland’s (TRIP / TRUFF) new app ‘iMicro’:
https://investingnews.com/news/agriculture-investing/red-light-holland-imicro-digital-care-app-and-telecounseling-goes-live/
Link to Wesana Health Holdings (WESA):
https://psilocybinalpha.com/news/wesana-health-commences-trading-on-the-cse
Image source: https://www.google.com/search?q=mike+tyson&rlz=1C1CHBF_enCA821CA821&sxsrf=ALeKk01FAUv0g0uK0yvLRLlkKOCgPEda6g:1621187634437&source=lnms&tbm=isch&sa=X&ved=2ahUKEwiagcLI4s7wAhWSF1kFHUeECgsQ_AUoAnoECAEQBA&biw=1600&bih=699#imgrc=Hwv5W22HvZQ3QM
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
editing by: @themyaholy
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #PsychedelicStocks #CMPS
In the heart of the Netherlands, legal psilocybin truffle retreats help seekers explore the benefits of psychedelics at the Essence Institute.
Who’s winning the psychedelics race and how do clinical trials work? This topic has been requested a lot lately so we decided to give you a rundown on the clinical trials system and the psychedelic-inspired companies who are furthest advanced at the moment. Of course, for now, MAPS is leading the race. However, other public companies such as Compass Pathways (CMPS) and MindMed (MMED / MNMD) are not far behind, for now.
Hopefully, this introductory video will help some new retail investors who are considering investing in biotech companies who do not te have an approved drug, to understand the importance that clinical trials need to play in their investing decisions.
Timestamps:
0:00 – Intro
1:34 – What is the clinical trial system?
2:15 – Preclinical
3:00 – Phase 0
3:32 – Phase I
5:45 – Phase II
8:26 – Phase III
10:28 – Phase IV
11:08 – Who’s winning the race?
11:16 – MAPS ( non-for-profit entity): Has already completed a Phase III study on MDMA to treat PTSD
12:02 – Compass Pathways (CMPS) has a Phase IIb trial to treat TRD with COMP360
12:28 – MindMed (MMED / MNMD) has completed a Phase IIa LSD study to treat Anxiety and will begin phase IIb this year. MindMed also has other Phase II studies involving LSD & Ibogaine (18-MC)
13:23 – Mydecine (MYCO) and CYBIN (CYBN) following suit
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
editing by: @themyaholy
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #Numi #CMPS
Treating traumatic brain injury with psychedelics will get a closer study in a partnership between the World Boxing Council and Wesana Health.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.